EGFR and neoplasm: Our data suggest patients with EGFR wild-type or unknown EGFR status tumours could start erlotinib but they should discontinue if they do not develop rash within 28 days, because these patients had no benefit in overall survival or progression-free survival, and in some subgroups overall survival could be reduced if erlotinib were taken continuously (panel).